Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19
https://techcrunch.com/2020/04/02/venture-backed-celularity-receives-fda-approval-for-early-trials-of-a-new-cell-therapy-for-covid-19/
Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19.
The company, which has raised at least $290 million to date (according to Crunchbase), uses “Natural Killer” (NK) cell therapies to boost the immune system’s disease-fighting response.
Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19
Apr 2, 2020, 3:31pm UTC
https://techcrunch.com/2020/04/02/venture-backed-celularity-receives-fda-approval-for-early-trials-of-a-new-cell-therapy-for-covid-19/
> Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19.
> The company, which has raised at least $290 million to date (according to Crunchbase), uses “Natural Killer” (NK) cell therapies to boost the immune system’s disease-fighting response.